Novo Nordisk's CEO expressed goodwill towards Pfizer's acquisition of Metsera, a biotech company with a promising obesity treatment, while affirming Novo's ongoing pursuit of similar assets to maintain its leadership in diabetes and obesity treatments, despite recent financial challenges.
Novo Nordisk remains committed to expanding its leadership in diabetes and obesity by pursuing strategic acquisitions despite a recent setback in acquiring Metsera. The company is actively seeking new assets that offer long-acting GLP-1 solutions to complement its existing pipeline, indicating potential investment opportunities in companies developing similar obesity and diabetes treatments. For those tracking investment signals, this highlights Novo's ongoing interest in acquiring biotech firms with innovative therapeutics in these areas.